🇺🇸 FDA
Patent

US 9290491

Crystalline forms of an 8-azabicyclo[3.2.1]octane compound

granted A61KA61K31/46A61K31/485

Quick answer

US patent 9290491 (Crystalline forms of an 8-azabicyclo[3.2.1]octane compound) held by Theravance Biopharma R&D IP, LLC expires Mon Mar 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance Biopharma R&D IP, LLC
Grant date
Tue Mar 22 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
2
CPC classes
A61K, A61K31/46, A61K31/485, A61K45/06, A61P